BEIJING AND CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc. (HKEX:1228), a China-based global biopharmaceutical company engaged in the research, development and commercialization of transformative therapies for rare diseases and rare oncology, today announced that She will participate in 2022 Morgan Stanley Virtual China Summit May 24-26, 2022.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. (HKEX: 1228) is a China-based global biopharmaceutical company dedicated to the research, development and commercialization of transformative therapies for rare diseases and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 11 assets, targeting prevalent rare diseases and rare oncology indications that have unmet need and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, and glioblastoma multiforme. CANbridge is also developing next-generation gene therapy development capability through collaboration with world-renowned researchers and biotech companies and in-house capability. CANbridge’s global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School and LogicBio.
To learn more about CANbridge Pharmaceuticals Inc., please visit: www.canbridgepharma.com.
Forward-looking statements
Forward-looking statements made in this article relate only to events or information as of the date the statements are made in this article. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, following the data on which the statements are made or to reflect the occurrence of unforeseen events. events. You should read this article in its entirety and be aware that our actual future results or performance may differ materially from what we expect. In this article, statements or references to our intentions or those of any of our directors or our company are made as of the date of this article. Each of these intentions may change in light of future development.
